GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases... Show more
GridAI Technologies Corp. (NASDAQ: GRDX) is a micro-cap company that has undergone a sharp strategic reinvention. Formerly known as Entero Therapeutics — and before that First Wave BioPharma — the company rebranded in December 2025 after acquiring Grid AI Corp., pivoting its center of gravity from clinical-stage gastrointestinal drug development toward a grid-edge, artificial intelligence (AI) energy-management platform while retaining its Adrulipase biotech asset. For investors, the forward-looking question is whether this dual-track business can secure enough capital and commercial traction to survive its transition.
GridAI Technologies Corp. now competes on two distinct fronts. Its Grid AI/AMPX platform uses real-time AI scheduling and optimization to orchestrate distributed energy resources (DERs) — devices such as batteries, solar systems, electric-vehicle (EV) chargers, and HVAC equipment — on behalf of utilities, retail energy providers, and large power users. This places the company within the fast-growing virtual power plant (VPP) and demand-response software market, where it faces larger, better-funded rivals, established energy-management incumbents, and in-house utility solutions.
The company's competitive advantage rests on its software-driven, device-agnostic architecture rather than proprietary hardware. While that model can scale quickly, it also makes the business dependent on third-party integration partners, data feeds, and interoperability with external ecosystems — a structural vulnerability if key relationships shift. Meanwhile, the legacy GI segment has been materially streamlined: Adrulipase is now the company's only active biopharmaceutical program, with Latiglutenase, Capeserod, CypCel, and Niclosamide all discontinued or divested.
Several forward-looking events could reshape the GRDX investment narrative. First, earnings and disclosure cadence matter disproportionately: the company's next quarterly report is estimated for November 2026, and each filing will be scrutinized for evidence that the AI segment's revenue can scale beyond its current nominal levels (roughly $124,000 for the first half of 2026). Second, capital-raising execution is pivotal. The company completed private placements of approximately $7.8 million in May 2026 and entered an $8.5 million financing agreement in July 2026; successfully drawing and deploying these funds — and resolving the registration-effectiveness condition tied to remaining proceeds — is critical to funding operations.
Third, Nasdaq compliance remains a live issue. The company received notice in April 2026 for failing to timely file its 10-K annual report, and it has a history of minimum-bid-price and stockholders'-equity compliance matters. Regaining and maintaining listing eligibility is a prerequisite for orderly capital markets access. Fourth, any decision to resume or further defer Adrulipase development represents a binary, capital-intensive swing factor. Finally, investor sentiment remains highly dependent on financing terms, as the resale of roughly 9.9 million registered shares could pressure the equity base.
The Grid AI/AMPX business is directly levered to the global energy transition. Rising electrification, growth in battery energy storage systems (BESS), EV adoption, and utility investment in grid flexibility all expand the addressable market for AI-driven load management and demand response. At the same time, this is a capital- and integration-intensive space where interest rates and financing conditions influence both customer procurement cycles and the company's own cost of capital. Higher-for-longer rates can delay utility and commercial deployment decisions, slowing revenue conversion.
The biotech side is governed by a different set of forces: regulatory pathway clarity, clinical trial costs, and the availability of development financing for a program that has no active trials as of late 2025. Because GridAI's revenue base is minimal and losses are significant, the company's trajectory is unusually sensitive to macro credit conditions and investor appetite for speculative, pre-revenue issuers.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the coming week or month. The platform is built to help users identify developing trends, evaluate potential breakouts or reversals, and explore predictions across a broad range of tradable instruments. It includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For a low-liquidity, catalyst-driven name like GRDX, combining trend signals with fundamental due diligence can add useful context to any forward-looking analysis.
Looking toward 2026 and beyond, GridAI Technologies Corp.'s fate hinges on whether its grid-edge AI platform can convert early customer interest into durable, recurring revenue while management stabilizes the balance sheet. Long-term structural drivers — grid modernization, DER proliferation, and the rise of AI-based energy orchestration — are real and supportive, but they favor scale, integration depth, and balance-sheet strength, attributes this company has yet to demonstrate. Margin sustainability, cost-structure discipline, and the pace of cash burn will be closely watched.
On the biotech side, Adrulipase retains a plausible development pathway but requires substantial new capital and a clear regulatory strategy to advance. Competitive threats are pronounced on both fronts: larger VPP and energy-software providers on one side, and well-capitalized rare-disease developers on the other. With no meaningful analyst consensus or published price targets currently available, the stock's outlook is defined less by ratings momentum and more by tangible execution milestones — financing completion, Nasdaq compliance, revenue inflection, and any strategic clarity on the legacy GI program. Investors should weigh these catalysts against the company's ongoing going-concern risk and the potential for further share dilution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GRDX has been loosely correlated with DCOY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if GRDX jumps, then DCOY could also see price increases.
| Ticker / NAME | Correlation To GRDX | 1D Price Change % | ||
|---|---|---|---|---|
| GRDX | 100% | +5.83% | ||
| DCOY - GRDX | 61% Loosely correlated | -5.73% | ||
| IVVD - GRDX | 60% Loosely correlated | +0.42% | ||
| RLMD - GRDX | 35% Loosely correlated | -4.46% | ||
| CABA - GRDX | 31% Poorly correlated | -4.35% | ||
| IMMP - GRDX | 29% Poorly correlated | +0.61% | ||
More | ||||
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for GRDX turned positive on September 21, 2026. Looking at past instances where GRDX's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on GRDX as a result. In 70 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
GRDX moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GRDX crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for GRDX moved above the 200-day moving average on October 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +11.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRDX advanced for three days, in 177 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 80 of 89 cases where GRDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The 10-day RSI Indicator for GRDX moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 32 cases where GRDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
GRDX broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GRDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.464) is normal, around the industry mean (2.988). P/E Ratio (-0.759) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (39.841) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.